Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether it can slow the progression of Parkinson’s.
Cure Parkinson’s has been a part of a group of Parkinson’s scientists, charity organizations, and patient advocates from around the world to help develop a new biological staging framework for Parkinson’s.
The build-up of a protein called alpha-synuclein has been considered one of the hallmarks of Parkinson’s. Recently, however, a group of scientists have called into question the ‘bad guy’ role of alpha-synuclein.
Recently, Cure Parkinson’s was pleased to see the results of one of our funded studies published in the Journal of Parkinson’s Disease.
In 2023, Cure Parkinson’s has funded five new preclinical projects. These preclinical projects address a wide range of ‘targets’ to understand which drugs and which targets should be further tested in a clinical trial.